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INTRODUCTION
Aberrant activation and expansion of CD4 + T helper (Th) cells and their secreted effector cytokines underlie the pathogenesis of many autoimmune diseases. The mechanism by which CD4 + T cells are abnormally activated and proliferate in these disorders remains elusive, but epigenetic dysregulation has been implicated in a range of conditions, including systemic lupus erythematosus rheumatoid arthritis, uveitis, systemic sclerosis and type I diabetes [1] [2] [3] [4] . Epigenetic modulation empowers the differential expression of lineage-specific signature genes in T cells to dictate T cell fate and function and regulate the immune system [5] . Consequently, therapeutics targeting epigenetic proteins are being developed to fine-tune the immune response with a view to clinical application in the treatment of autoimmune disorders [6, 7] .
Chromatin regulators are a class of proteins that affect gene expression by influencing the accessibility of transcription factors and co-factors to chromosomal DNA. Typically, chromatin regulators include writer proteins that add post-translational modifications (PTMs) to histones, reader proteins that recognize PTMs, and eraser proteins that remove PTMs from histones [8] .
Bromodomain extra-terminal (BET) family proteins belong to chromatin readers.
They are comprised of four members: BRD2, BRD3, BRD4, and BRDT [9] . BET proteins recognize acetylated lysine residues through their bromodomains, recruit transcriptional coactivators, and promote pro-inflammatory and oncogenic gene expression [9, 11] , and it has been reported that BET inhibition promotes cell differentiation, inhibits proliferation, and suppresses inflammation [10] .. Targeted inhibition of BET proteins has therefore been shown to be protective in several autoimmune disease models [12] [13] [14] [15] .
In 2010 the first two BET inhibitors, JQ1 and I-BET, were reported simultaneously from two different groups [15, 16] . JQ1 suppresses inflammatory responses mediated by Th17 through disruption of BRD4 functioning and its downstream signaling cascades [14, 17] . However, its systemic toxicity and insufficient pharmacokinetic effect in vivo have limited its potential for clinical application [18, 19] . A new BET inhibitor, OTX015, has been reported to be better tolerated in clinical trials for hematologic malignancies and solid tumors [20, 21] . Given the potential to extend its application to autoimmune conditions, we sought to interrogate the effect of OTX015 on the classical proinflammatory CD4 + T cell subsets in vitro as the first stage in its pre-clinical evaluation for therapeutic application. In this study we show that murine and human subsets of CD4 + T cells respond differently to OTX015 and that OTX015 preferentially acts on human Th17 cells.
MATERIALS AND METHODS

Healthy Controls
CD4 + T cells were obtained from up to 80 ml peripheral blood from healthy controls (HCs) following informed consent in accordance with National Health Service Research Ethic Committee approved protocols at the University Hospitals Bristol Foundation Trust, United Kingdom (04/Q2002/84). Written informed consent was obtained from all study participants.
Materials
Both OTX015 and JQ1 (Stratech Scientific, UK) were dissolved in DMSO to make a stock solution of 10 mM. Aliquots were kept at -80 o C for up to 6 months and diluted with appropriate culture media for in vitro use. Murine Recombinant murine IL-6 and IL-12 were purchased from PeproTech (USA) and recombinant human TGF- was purchased from R&D systems (USA).
Cell Isolation
CD4 + T cells from HCs were enriched by negative selection using the RosetteSep® Human CD4 + T cell Enrichment Cocktail (Stemcell Technologies, Canada) according to the manufacturer's instruction. CD4 + T cells were removed from the interface between the plasma and density gradient and washed twice with RPMI-1640 containing 10% (v/v) fetal calf serum (FCS) (Gibco, USA). The purity of CD4 + T cells achieved was greater than 95%. For murine CD4 + T cell isolation, cells from lymph nodes and spleens were isolated and processed into single cell suspension. CD4 + T cells were isolated using the CD4 (L3T4) Microbeads (Miltenyi Biotec, Germany) according to manufacturer's instruction. The purity of CD4 + T cells achieved was greater than 95%.
Fluorescence-Activated Cell Sorting (FACS)
Non-specific murine antibody binding was blocked by incubating cells with 24G2 supernatant for 10 minutes at double positive cells (CCR6 + CXCR3 + CCR4 -). All FACS was performed using either the BD Aria (murine) or the BD Influx Systems (human) (BD Biosciences, USA) and routinely > 95% purity was achieved.
Flow Cytometry
As for FACS surface staining, nonspecific antibody binding was blocked with 24G2 supernatant followed by incubation with primary antibodies against surface markers. Intracellular cytokine analysis was carried out by incubating the cells with 20 ng/ml PMA, 1 µM ionomycin and 1 µl/ml Golgistop (BD Bioscience, USA) for the last 4 hours of culture. Cells were fixed, permeabilized with the Cytofix/perm solution (BD Bioscience, USA) and stained with intracellular cytokine antibodies. Cells were washed with PBS containing 2% FCS twice. The LIVE/DEAD TM fixable dead cell stain kit (Thermofisher Scientific, USA) was used to exclude dead cells from analysis. All samples were acquired using the BD TM LSR II or BD LSR Fortessa TM X-20 (BD Bioscience, USA) and
data were analyzed with FlowJo v10 (Tree Star Inc, USA).
Murine CD4 + T Cell In Vitro Assays
To measure cell proliferation, isolated CD4 + T cells were stained with CellTrace TM Violet and seeded into 96-well plates (0.1 million cells/well) precoated with 5 µg/ml anti-CD3 and 2 µg/ml anti-CD28. RPMI1640 Culture media was supplemented with polarization cytokines and BET inhibitor: Th1 (20 ng/ml mIL-12, 100 ng/ml anti-IL-4) and Th17 (20 ng/ml mIL-6, 1 ng/ml TGF-1, 100 ng/ml anti-IL-4, 100 ng/ml anti-IFN-). All cells were cultured with RPMI-1640 containing 10% FCS, Pen/Strep and 2-mercaptoethanol in a humidified incubator containing 5% CO2 at 37 o C. (Hs_01076122_m1) and TBX21 (Hs00203436_m1).
Human CD4 + T Cell In Vitro Assays
Statistics
The statistical analyses were performed with Prism Graphpad 7.0 (GraphPad Software, USA). Mann-Whitney U test, Kruskal-Wallis test or twoway ANOVA test were used accordingly.
RESULTS
OTX015 differentially affects murine naïve and memory CD4 + T cells
JQ1 has previously been shown to suppress cytokine expression in Th17 cells [14] . As OTX015 is a new BET inhibitor, we first tested whether OTX015 could suppress Th1 and Th17 subsets induced from FACS sorted murine naïve CD4 + T cells. We polarized these cells into Th1 or Th17 subsets in the presence or absence of 50 nM of OTX015 for 72 hours ( Figure 1A and 1B) , and found that in our in vitro system OTX015 had a more profound effect on IFN- from induced Th1 than on IL-17 from Th17 cells. The optimal concentration of OTX015 and treatment duration were selected according to the cell viability and the expression of cytokines from dose-dependent and time-course studies ( Supplementary Figure 2) . At 50 nM, no significant viability change was observed between OTX015 treated or untreated control cultures (Supplementary Figure 2) . However, at higher concentrations, OTX015 was more detrimental to the viability of murine than human CD4 + T cells. In addition, we confirmed that OTX015 and JQ1 had equivalent inhibitory effects on murine CD4 + T cell subsets, as indicated by the cytokine production and cell proliferation of Th1 and Th17 subsets after treatment ( Supplementary Figure 3) .
These results indicated that OTX015 could efficiently suppress differentiation of CD4 + T cells from naïve cells.
Naïve and memory CD4 + T cells have different roles in the immune system.
Their epigenetic status and epigenetic alterations toward stimulation are also different [22] [23] [24] . We therefore investigated the effect of OTX015 on stimulated memory CD4 + T cells. Murine CD4 + memory T cells were also sorted by FACS and stimulated with anti-CD3/CD28 in the presence or absence of OTX015 for 24 hours. Strikingly, OTX015 had no effect on the production of IFN- or IL-17
in murine memory CD4 + T cells ( Figure 1C and 1D ). These results indicate that different subtypes of CD4 + T cells may respond differently to epigenetic regulators.
OTX015 preferentially inhibits IL-17 over IFN- in human CD4 + T cells
To test the potential to translate our murine findings to human disease, we applied OTX015 on human CD4 + T cells for 5 days. OTX015 suppressed, in a dose-dependent manner, both human CD4 + T cell proliferation (Figure 2A expression but failed to significantly suppress IFN-. Next, we next conducted a comparison of JQ1 and OTX015, and found that there was no significant difference between these two BET inhibitors in either affecting cell proliferation or cytokine production (Supplementary Figure 5) . These results were different from that of murine cells, prompting us to question whether OTX015's differential effect on naïve and memory T cells would be consistent across species.
OTX015 preferentially suppresses IL-17 in human memory CD4 + T cells.
Next, we tested OTX015 on different human CD4 + T cell subpopulations.
Human naïve and memory CD4 + T cells subsets were isolated by FACS and activated in vitro with or without OTX015 for 5 days. As shown in Figure 3A However, OTX015 had limited suppressive effects on the production of IFN-γ from naïve cells and even caused a slight increase in IFN- production from TEM ( Figure 3E ). Consitent with this, for naïve CD4 + T cells, there was no significant change in the level of TBX21 and RORC between OTX015 treated and control group. But in TCM, RORC was significantly inhibited by OTX015.
In TEM cells, we saw an increase in TBX21 and a decrease in RORC by OTX015 ( Figure 3G ).
OTX015 inhibits Th1, Th17 and IFN- & IL-17 double positive cell proliferation but preferentially acts on Th17 cytokines in human Th subsets
To study the effect of OTX015 on human CD4 + T cell subsets in more detail, Th1, Th17 and IFN- & IL-17 double positive cells were sorted based on the expression of chemokine receptors and activated for 5 days with 2,500 nM OTX015. As shown in Figure 4A Figure 4D-4G ). This result is highly consistent with that in human memory T cells.
DISCUSSION
In this study, we have shown that the BET inhibitor OTX015 significantly inhibits CD4 + T cell proliferation and differentially suppressed their expression of IL-17 and IFN- across murine and human CD4 + T cell subsets. Our findings were confirmed with detailed dose-response and time-course studies in both murine and human CD4 + T cells. BET inhibitors have been extensively studied in cancer and inflammatory diseases. JQ1 is a thoroughly-researched representative BET inhibitor and is reported to selectively block IL-17A and IL-IFN- under Th1 biased conditions [14] . I-BET-762 has been also reported to downregulate IL-17 and IFN- in murine T cells [25] . However, JQ1 has a relatively short half-life in the plasma: 0.9 hours with intravenous injection of 5 mg/kg or 1.4 hours with oral administration of 10 mg/kg [26] . Moreover, it has been shown to cause severe weight loss and leukopenia in mice [19] . These drawbacks limit the clinical application of JQ1. OTX015, as a new BET inhibitor, belongs to the azepine chemical family like JQ1. It is the first oral BET inhibitor which has been tested in clinical trials in oncology [20, 21, 27] . Our results have shown that OTX015 and JQ1 have similar inhibitory effects on the inflammatory cytokine production from murine and human CD4 + T cells. Given that OTX015
is much safer and more stable than JQ1, OTX015 therefore has the potential to also be developed for the treatment of autoimmune diseases. Although naïve and memory CD4 + T cells have over 95% similarity in global gene expression, they display different expression patterns of immunerelated genes, which reflects the difference in epigenetic status of these two subsets [22] . In support of this notion, previous studies showed that T cells exhibited epigenetic remodeling between initial stimulation and subsequent restimulation [23, 24] . Our results demonstrate that naïve and memory T cells respond differently to the epigenetic "reader" inhibition. OTX015 could efficiently suppress IFN- in induced murine Th1 cells, but not spontaneously secreted IFN- from murine memory T cells. The results were replicated using human total and memory T cells. Our results therefore hint that the epigenetic context must be considered when applying BET targeting compounds. It is also interesting that IL-17 but not IFN- was suppressed in human memory CD4 + T cells. This may be therapeutically desirable in the context of chronic inflammation as persistent IFN- expression has potential benefit in the late stages of conditions such as autoimmune uveitis [29] .
Downregulation of IFN- in
Our results showed that both Th cell proliferation and cytokine production were suppressed by OTX015. To exclude a general suppressive effect, we performed qPCR to quantify the mRNA expression of critical transcription factors in human CD4 + T cell subsets. RORC but not TBX21 was suppressed in human central memory T cells by OTX015. In TEM, we even saw an elevated expression of TBX21, which is different from that in naïve CD4 + T cell subsets.
These results echo the protein changes reported for JQ1, in which there was reduction of RORC and RORA, but not TBX21, GATA3 or FOXP3 in corresponding CD4 + T cell subtypes [14] .
CONCLUSION
In summary, we have shown that the BET inhibitor OTX015 can efficiently suppress the proliferation of murine and human Th cells as well as subsetspecific production of their pro-inflammatory cytokines. In addition, we have also demonstrated that both murine and human naïve CD4 + T cells reacted differently to OTX015 when compared to murine and human memory CD4 + T cells. These results indicate the potential benefits and also immune contextdependent caveats of developing BET inhibitors to target inflammatory diseases. 
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